We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

19 hedge funds and large institutions have $5.31M invested in Moleculin Biotech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

198% more capital invested

Capital invested by funds: $1.78M → $5.31M (+$3.53M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

5% less funds holding

Funds holding: 20 → 19 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.27M
2
Renaissance Technologies
Renaissance Technologies
New York
+$818K
3
BlackRock
BlackRock
New York
+$78.8K
4
Morgan Stanley
Morgan Stanley
New York
+$21.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$19K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$294K
2
AC
Armistice Capital
New York
-$179K
3
Bank of America
Bank of America
North Carolina
-$20K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$13.6K
5
IWP
Icon Wealth Partners
Texas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.35M +$2.27M +836 +235%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.04M +$818K +301 +430%
WIC
3
Whitegate Investment Counselors
New Hampshire
$190K – – –
Truist Financial
4
Truist Financial
North Carolina
$175K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$158K – – –
BlackRock
6
BlackRock
New York
$141K +$78.8K +29 +138%
Northern Trust
7
Northern Trust
Illinois
$60K – – –
Bank of New York Mellon
8
Bank of New York Mellon
New York
$41K – – –
Morgan Stanley
9
Morgan Stanley
New York
$39K +$21.7K +8 +133%
RJFSA
10
Raymond James Financial Services Advisors
Florida
$24K +$8.15K +3 +50%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$21K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$20K +$19K +7 New
LNWWM
13
Laird Norton Wetherby Wealth Management
California
$13K – – –
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$12K -$13.6K -5 -56%
ACS
15
Archford Capital Strategies
Illinois
$4K – – –
PFGIA
16
Patriot Financial Group Insurance Agency
Massachusetts
$3K – – –
CTB
17
Country Trust Bank
Illinois
$3K +$2.72K +1 New
Wells Fargo
18
Wells Fargo
California
$3K +$2.72K +1 New
APA
19
American Portfolios Advisors
New York
$2.5K – – –
Carson Wealth (CWM LLC)
20
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
GRP
21
Global Retirement Partners
California
$1K – – –
PWMG
22
Prestige Wealth Management Group
New Jersey
$1K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$1K – – –
CH
24
CVI Holdings
Delaware
– -$294K -161 Closed
AC
25
Armistice Capital
New York
– -$179K -98 Closed
1
2

MBRX Hedge Fund Activity: Q2 2019 in Review

19 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2019, worth a combined $5.31M — up 198% from $1.78M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.

The largest buyer was Vanguard Group, adding an estimated $2.27M. The largest seller was CVI Holdings, exiting entirely with an estimated $294K sold.

  • 19 institutional investors held Moleculin Biotech (MBRX) as of Q2 2019, down from 20 in Q1 2019.
  • Funds reported $5.31M of Moleculin Biotech stock for Q2 2019, up 198% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q2 2019 and 4 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q2 2019 was Vanguard Group, an estimated $2.27M added.
  • The largest Moleculin Biotech seller in Q2 2019 was CVI Holdings, an estimated $294K sold.

Based on aggregated 13F filings for Q2 2019.